VRP Verona Pharma Plc

 
TIDMVRP 
 
Verona Pharmaplc 
 
                      ("Verona Pharma" or the "Company") 
 
                              Director's Dealing 
 
20 January 2015, Cardiff - Verona Pharma plc (AIM: VRP) yesterday received 
notification that on 19 January 2015 Mr Stuart Bottomley, Non-Executive 
Director of the Company, purchased via his SIPP 1,000,000 ordinary shares of 
0.1p each in the Company ("Ordinary Shares") at a price of 1.5 pence per share. 
 
Following the acquisition, Mr Bottomley will have an interest in the Company of 
20,000,000 Ordinary Shares, representing 1.98% of the Company's issued ordinary 
share capital. 
 
                                    -Ends- 
 
For further information please contact: 
 
Verona Pharma plc                       Tel: +44 (0) 20 3283 4200 
 
Jan-Anders Karlsson, CEO 
 
N+1 Singer                              Tel: +44 (0)20 7496 3000 
 
Aubrey Powell / Jen Boorer 
 
FTI Consulting                          Tel: +44 (0)20 3727 1000 
 
Julia Phillips / Simon Conway 
 
Notes to Editors 
 
About Verona Pharma plc 
 
Verona Pharma plc is a UK-based clinical stage biopharmaceutical company 
focused on the development of innovative prescription medicines to treat 
respiratory diseases with significant unmet medical needs, such as COPD, asthma 
and cystic fibrosis. Verona Pharma's lead drug, RPL554, is a first-in-class 
drug currently in Phase II trials as a nebulised treatment for acute 
exacerbations of COPD in the hospital setting. The drug is a 
dual phosphodiesterase (PDE) 3/4 inhibitor and therefore has both 
bronchodilator and anti-inflammatory effects, which are essential to the 
improvement of patients with COPD and asthma. Verona Pharma is also building a 
broader franchise around RPL554 to maximise its value, both to patients and to 
investors. This includes the very significant markets for COPD and asthma 
maintenance therapy. The Company is also exploring the potential of the drug in 
different diseases, such as cystic fibrosis, where it is in pre-clinical 
testing. 
 
 
 
END 
 

Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jun 2024 to Jul 2024

Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jul 2023 to Jul 2024